PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Bioengineered Schizochytrium sp. meal hydrolysates (MESH) ameliorated bowel inflammation in mice, reducing body weight loss and colonic histological damage [PMID: 29959357]
Increased intake of EPA and DHA (sourced from fish or algae like Schizochytrium sp.) may benefit athletes by controlling inflammation and supporting muscle mass maintenance [PMID: 38068783]
Dietary Schizochytrium sp. powder improved weight gain rate and specific growth rate in juvenile darkbarbel catfish [PMID: 42328303]
Broilers supplemented with Schizochytrium sp. powder showed significantly higher weight gain compared to salmon oil or flaxseed oil groups [PMID: 35565592]
Safety & adverse effects
Pregnancy & lactation
Evidence summary
PubMed sources
- 1.PMID: 38068783 (2023) — Athletes Can Benefit from Increased Intake of EPA and DHA-Evaluating the Evidence. · Nutrients
- 2.PMID: 37731016 (2023) — Simultaneous DHA and organic selenium production by Schizochytrium sp.: a theoretical basis. · Scientific reports
- 3.PMID: 36454215 (2022) — Modulating DHA-Producing Schizochytrium sp. toward Astaxanthin Biosynthesis via a Seamless Genome Editing System. · ACS synthetic biology
- 4.PMID: 30410471 (2018) — Prospects on the Use of Schizochytrium sp. to Develop Oral Vaccines. · Frontiers in microbiology
- 5.PMID: 12052009 (2002) — Safety assessment of DHA-rich microalgae from Schizochytrium sp.